A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study

Lainie P. Martin, Michael Sill, Mark S. Shahin, Matthew Powell, Paul Disilvestro, Lisa M. Landrum, Stephanie L. Gaillard, Michael J. Goodheart, James Hoffman, Russell J. Schilder

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.

Medicine & Life Sciences